FDA approves Roche’s Tecentriq + lurbinectedin as first-line maintenance therapy for lung cancer
Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study
Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study
With global certification in place, the Ambernath site expands Supriya’s footprint beyond APIs into high-margin formulations
Trastuzumab Deruxtecan 100mg/5mL vial lyophilized powder for concentrate for solution for infusion is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors
Panacea Biotec receives Rs. 315 crore LoA from UNICEF
Proposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio
A Post Graduate in Science faculty and has a wide experience spanning over 35 years in the field of manufacturing Bulk Drugs and Active Pharmaceutical Intermediaries
The expansion will significantly enhance AbbVie’s ability to meet growing global demand for biologics, particularly in oncology and immunology
Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine
Subscribe To Our Newsletter & Stay Updated